Semaglutide placebo

DRUG8 trials

Conditions

Alzheimer DiseaseGlucose Intolerance After a Recent History of Gestational DiabetesGlycemic Control for Diabetes MellitusInsulin Sensitivity/ResistanceLipidomicsMetabolic SyndromeMetabolomicsMild Cognitive Impairment

Phase 2

Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

CompletedNCT05016882

Novo Nordisk A/SNon-alcoholic Steatohepatitis

Start: 2021-08-31End: 2025-03-14Updated: 2025-11-19

COMMETS- Combination MCI Metabolic Syndrome

RecruitingNCT06072963

Rutgers, The State University of New JerseyAlzheimer Disease, Metabolic Syndrome, Mild Cognitive Impairment

Start: 2024-01-30End: 2028-12-01Target: 80Updated: 2024-03-22

Phase 3

Semaglutide for the Treatment of Glucose Intolerance in Women with Prior Gestational Diabetes

RecruitingNCT05569772

Universitaire Ziekenhuizen KU LeuvenGlucose Intolerance After a Recent History of Gestational Diabetes

Start: 2023-09-14End: 2028-12-31Target: 252Updated: 2025-02-10

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)

CompletedNCT05890976

Novo Nordisk A/SObesity, Overweight

Start: 2023-05-30End: 2025-01-16Updated: 2026-01-22

A randomised double-blind placebo-controlled clinical study investigating the effects of semaglutide s.c. once-weekly versus placebo on central and peripheral inflammation in participants with Alzheimer’s disease.

CompletedCTIS2023-506825-13-00

Novo Nordisk A/Sboth of the Alzheimer’s type, Mild cognitive impairment (MCI) or mild dementia

Start: 2023-07-25End: 2025-06-26Target: 13Updated: 2025-02-17

Long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (FOCUS)

Active, not recruitingCTIS2023-506827-26-00

Novo Nordisk A/Sintensification of glycaemic control has also been associated with an initial worsening of diabetic retinopathy. This phenomenon is known as “early worsening”. The rationale of this trial is to establish the long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (T2D) using validated and standardised ophthalmic assessments. This trial is a post-authorisation safety study (PASS) conducted as a commitment to the European Medicines Agency, While it is well-established that long-term good glycaemic control will reduce the risk of diabetic retinopathy development and progression

Start: 2019-05-02Target: 589Updated: 2025-12-16

Semaglutide Treatment in Type 1 Diabetes

Not yet recruitingNCT06909006

Nordsjaellands HospitalGlycemic Control for Diabetes Mellitus, Insulin Sensitivity/Resistance, Lipidomics +6

Start: 2025-10-31End: 2028-06-30Target: 122Updated: 2025-08-08

Phase 4

eHealth Based treatment of AdolescenT obesiTy with Low energy diet and sEmaglutide (eBATTLE Obesity)

RecruitingCTIS2023-506289-29-00

Vestfold Hospital TrustObesity

Start: 2025-02-28Target: 220Updated: 2025-01-24

Related Papers

From cause to consequence: Insights into incident diabetes mellitus after hepatic steatosis